Advocacy News – April 30, 2026
The big picture: On April 23, 2026, the U.S. Department of Justice reclassified certain marijuana products to Schedule III under the Controlled Substances Act – a major federal shift after decades of Schedule I treatment.
Why it matters: This move recognizes medical use and lowers perceived risk – bringing new implications for workplace policies, especially under the Americans with Disabilities Act (ADA).
What changed:
- Covers FDA-approved marijuana drugs and state-regulated medical marijuana
- Does not legalize recreational use federally
- DOT-regulated safety roles (e.g., pilots, truck drivers) are unchanged under U.S. Department of Transportation rules
Bottom line: Employers may need to treat medical marijuana like other prescribed medications.
- Past: Marijuana use = “illegal drug use” → no accommodation required
- Now: Lawful medical use is no longer categorically illegal
- Result: Employers should engage in the ADA interactive process for qualified employees
- However, employers can still prohibit on-the-job impairment and safety-sensitive restrictions remain valid
- THC testing isn’t off the table — but it’s more regulated
Go deeper: This isn’t full legalization – but it’s a meaningful legal shift. Employers who treat it as business-as-usual risk falling out of compliance. Check out the full legal analysis from our friends at Miller Canfield.